We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Schering Partners with ChemDiv in Medicinal Chemistry

Read time: Less than a minute

ChemDiv, Inc. has announced that it has entered into a medicinal chemistry research partnership with Schering AG, Berlin, Germany.

The collaboration between the companies will last a minimum of two years, with an extension clause dependent upon meeting defined milestones under the contract.

Under the terms of the collaboration, ChemDiv will apply its expertise in small molecule chemistry to support the ongoing medicinal chemistry programs at Schering.

Schering will have access to a wide range of services including chemistry development, synthesis of hit and lead series, as well as scale up production of advanced intermediates.

ChemDiv will utilize its global logistics platform to support the collaboration with on time formatting and distribution services.

Alexander Kiselyov, VP of Global Chemistry at ChemDiv, Inc. commented, "We are delighted to expand our relationship with Schering AG under the new collaboration agreement.”

“We see this as an acknowledgement of the success of ChemDiv's discovery services. ChemDiv will continue to commit its expertise and resources to add value to Schering's discovery programs."